Table 4 Adverse events of any grade by lines of therapy (safety population)

From: Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment

 

1 previous line of therapy

⩾ 2 previous lines of therapy

 

KRd

n=182

Rd

n=154

KRd

n=210

Rd

n=235

AEs occurring in ⩾10% of patients in any subgroup (preferred terms), n (%)

Diarrhea

83 (45.6)

59 (38.3)

83 (39.5)

72 (30.6)

Anemia

82 (45.1)

66 (42.9)

85 (40.5)

89 (37.9)

Fatigue

65 (35.7)

45 (29.2)

64 (30.5)

74 (31.5)

Neutropenia

59 (32.4)

45 (29.2)

89 (42.4)

86 (36.6)

Muscle spasms

55 (30.2)

28 (18.2)

49 (23.3)

54 (23.0)

URTI

54 (29.7)

29 (18.8)

58 (27.6)

46 (19.6)

Cough

50 (27.5)

29 (18.8)

63 (30.0)

38 (16.2)

Pyrexia

49 (26.9)

33 (21.4)

63 (30.0)

48 (20.4)

Thrombocytopenia

49 (26.9)

32 (20.8)

65 (31.0)

56 (23.8)

Nasopharyngitis

48 (26.4)

28 (18.2)

36 (17.1)

35 (14.9)

Hypokalemia

45 (24.7)

25 (16.2)

63 (30.0)

27 (11.5)

Edema peripheral

45 (24.7)

28 (18.2)

40 (19.0)

47 (20.0)

Constipation

43 (23.6)

27 (17.5)

36 (17.1)

40 (17.0)

Dyspnea

42 (23.1)

22 (14.3)

34 (16.2)

36 (15.3)

Insomnia

38 (20.9)

23 (14.9)

37 (17.6)

40 (17.0)

Asthenia

35 (19.2)

29 (18.8)

35 (16.7)

27 (11.5)

Nausea

34 (18.7)

26 (16.9)

44 (21.0)

29 (12.3)

Hypocalcemia

33 (18.1)

16 (10.4)

30 (14.3)

29 (12.3)

Pneumonia

31 (17.0)

19 (12.3)

37 (17.6)

37 (15.7)

Bronchitis

29 (15.9)

21 (13.6)

45 (21.4)

33 (14.0)

Back pain

27 (14.8)

35 (22.7)

40 (19.0)

43 (18.3)

Hypophosphatemia

27 (14.8)

13 (8.4)

25 (11.9)

16 (6.8)

Hyperglycemia

26 (14.3)

17 (11.0)

23 (11.0)

21 (8.9)

Rash

25 (13.7)

23 (14.9)

27 (12.9)

37 (15.7)

Arthralgia

22 (12.1)

27 (17.5)

27 (12.9)

24 (10.2)

Dizziness

22 (12.1)

19 (12.3)

26 (12.4)

25 (10.6)

Pain in extremity

22 (12.1)

19 (12.3)

24 (11.4)

22 (9.4)

Headache

21 (11.5)

9 (5.8)

32 (15.2)

22 (9.4)

Hypertension

21 (11.5)

7 (4.5)

35 (16.7)

20 (8.5)

RTI

20 (11.0)

17 (11.0)

23 (11.0)

22 (9.4)

Vomiting

20 (11.0)

16 (10.4)

27 (12.9)

16 (6.8)

Decreased appetite

19 (10.4)

17 (11.0)

25 (11.9)

18 (7.7)

Bone pain

15 (8.2)

18 (11.7)

24 (11.4)

18 (7.7)

AEs of interest (grouped terms), n (%)

 Cardiac failurea

10 (5.5)

8 (5.2)

15 (7.1)

8 (3.4)

 Ischemic heart diseaseb

12 (6.6)

7 (4.5)

11 (5.2)

11 (4.7)

 Acute renal failurec

20 (11.0)

10 (6.5)

13 (6.2)

18 (7.7)

  1. Abbreviations: AE, adverse event; CAD, coronary artery disease; KRd, carfilzomib, lenalidomide and dexamethasone; MI, myocardial infarction; Rd, lenalidomide and dexamethasone; RTI, respiratory tract infection; URTI, upper respiratory tract infection.
  2. aIncluded: cardiac failure, congestive cardiac failure, pulmonary edema, hepatic congestion, cardiopulmonary failure, acute pulmonary edema, acute cardiac failure and right ventricular failure.
  3. bIncluded: angina pectoris, MI, acute MI, increased blood creatinine phosphokinase, CAD, myocardial ischemia, coronary artery occlusion, increased troponin, increased troponin T, acute coronary syndrome, abnormal cardiac stress test, cardiomyopathy stress, unstable angina, coronary artery stenosis, abnormal electrocardiogram ST-T segment and abnormal electrocardiogram T wave.
  4. cIncluded: acute renal failure, renal failure, renal impairment, azotemia, oliguria, anuria, toxic nephropathy and prerenal failure.
Back to article page